Patent intelligence · US
US 9708291
Intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl)-(2-chlorophenyl)-methanone
Intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-…
Patent details — US 9708291
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 18, 2017
- Expiration
- Jul 13, 2037
- Applicant
- VANDA PHARMACEUTICALS INC.
- Claims
- 12
- CPC classes
- A61P, A61P1/04, A61P1/06, A61P11/00
Quick answer
US 9708291 (Intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl)-(2-chlorophenyl)-methanone) is held by VANDA PHARMACEUTICALS INC.. Status: granted. Granted Jul 18, 2017. Expires Jul 13, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- VANDA PHARMACEUTICALS INC.
- Grant date
- Expiration
- Claims
- 12
- CPC classes
- A61P, A61P1/04, A61P1/06, A61P11/00, A61P11/06, A61P13/10
More from VANDA PHARMACEUTICALS INC.
Related pharmaceutical patents in our USPTO index.
-
US 12427132
Method of improving sleep
granted -
US 12419869
Methods of treating multiple sclerosis
granted -
US 12409167
Pharmaceutical combination comprising a selective S1P1 receptor agonist
granted -
US 12403134
Method for improving or enhancing cognition
granted -
US 12357616
Methods of treating multiple sclerosis
granted -
US 12336980
Dosing regimen for a selective S1P1 receptor agonist
granted -
US 12318375
Method of treatment with tradipitant
granted -
US 12201604
Treatment of circadian rhythm disorders
granted
Frequently asked questions
What is US patent 9708291?
US 9708291 (Intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl)-(2-chlorophenyl)-methanone) is held by VANDA PHARMACEUTICALS INC.. Status: granted. Granted Jul 18, 2017. Expires Jul 13, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9708291?
VANDA PHARMACEUTICALS INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 96 pharmaceutical patents for this assignee.
When does US 9708291 expire?
Our index shows an expiration date of Jul 13, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.